NRXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neuraxis Inc (NRXS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as coverage expansion and revenue growth, the lack of strong trading signals, neutral sentiment from hedge funds and insiders, and the company's ongoing losses make it less compelling for immediate investment.
The stock's technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD histogram is negative and contracting, and RSI is in the neutral zone. The stock is trading near its resistance level (R1: 4.957) with a pre-market price of 4.85, suggesting limited upside in the short term.
The company achieved a significant coverage expansion, adding approximately 45M lives and unlocking a large pediatric opportunity. Revenue increased by 21.72% YoY in Q3 2025.
Net income remains negative at -$2.32M, and EPS dropped by 4% YoY. Gross margin also declined slightly to 83.3%. Technical indicators do not show strong upward momentum.
In Q3 2025, revenue grew by 21.72% YoY to $811,414, but the company remains unprofitable with a net loss of $2.32M. EPS decreased by 4% YoY, and gross margin dropped slightly by 2.5%.
Craig-Hallum recently raised the price target to $8 from $7 and maintained a Buy rating, citing the company's coverage expansion as a significant growth opportunity.
